2005
- 2005/12/15
- Takara Bio Inc. to supply RetroNectin® to City of Hope's HIV/AIDS gene therapy study
- 2005/12/13
- MolMed S.p.A., Takara Bio's strategic partner in gene therapy, presents positive results of its Phase I/II clinical trial of HSV-TK gene therapy in high risk leukemia
- 2005/09/01
- Notice of Completion of Acquisition of Clontech Operations
- 2005/07/29
- Notice of Increase in Capital of Subsidiary
- 2005/07/01
- Takara Bio to Acquire Clontech Unit of BD Biosciences
- 2005/03/14
- Takara Bio establishes an endowed chair in Mie University School of Medicine and jointly promotes the clinical development of T-cell receptor (TCR) gene therapy targeting esophageal cancers
- 2005/01/24
- Patents obtained in Japan and the United States for biomarkers useful in treatment of refractory leukemia
- 2005/01/13
- Takara Bio Inc. announced that its partner MolMed S.p.A. plans to enter into Phase III clinical studies on HSV-TK gene therapy project this year
